LEADER 02079nmm a2200457 u 4500
001 EB001902371
003 EBX01000000000000001065280
005 00000000000000.0
007 cr|||||||||||||||||||||
008 201006 ||| eng
100 1 |a Shankar-Hari, Manu 
245 0 0 |a Convalescent plasma therapy as a treatment for COVID-19  |h Elektronische Ressource  |c Manu Shankar-Hari 
260 |a London  |b Henry Stewart Talks  |c 2020, 2020 
300 |a 1 streaming audio file (15 min.)) 
505 0 |a Contents: What is convalescent plasma therapy -- Does this treatment confer long-lasting immunity? -- Mechanism of action of therapeutic antibodies -- Counterindications with plasma transfusions -- The need for lengthy clinical trials -- Preliminary assessment of convalescent plasma therapy in a clinical trial -- When might this treatment be approved, and how fast can it be delivered? 
653 |a Coronavirus infections / Treatment 
653 |a Antibodies, Viral / therapeutic use 
653 |a COVID-19 
653 |a Viral antibodies 
653 |a severe acute respiratory syndrome coronavirus 2 
653 |a Pneumonia, Viral / prevention & control 
653 |a Blood plasma 
653 |a Clinical trials 
653 |a Blood Donors 
653 |a Pneumonia, Viral / therapy 
653 |a Clinical Trials as Topic 
653 |a Coronavirus infections / therapy 
653 |a Coronavirus infections / prevention & control 
653 |a Betacoronavirus / immunology 
653 |a COVID-19 (Disease) / Research 
653 |a Antibodies, Viral / administration & dosage 
653 |a Coronavirus infections / immunology 
653 |a Antibodies, Viral / blood 
653 |a Immunization, Passive 
041 0 7 |a eng  |2 ISO 639-2 
989 |b HST  |a Henry Stewart Talks 
490 0 |a Research and clinical interviews 
500 |a Audio interview. - Title from title frames. - Mode of access: World Wide Web 
856 4 0 |u https://hstalks.com/bs/4323  |x Verlag  |z Streaming video file 
856 4 2 |u https://hstalks.com/bs/p/1060  |3 Series 
082 0 |a 570